Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Inhibrx Biosciences (INBX) Research & Development: 2023-2025

Historic Research & Development for Inhibrx Biosciences (INBX) over the last 3 years, with Sep 2025 value amounting to $28.5 million.

  • Inhibrx Biosciences' Research & Development fell 26.63% to $28.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.0 million, marking a year-over-year decrease of 52.05%. This contributed to the annual value of $203.7 million for FY2024, which is 6.32% up from last year.
  • As of Q3 2025, Inhibrx Biosciences' Research & Development stood at $28.5 million, which was up 28.15% from $22.3 million recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' Research & Development ranged from a high of $82.1 million in Q4 2023 and a low of $22.3 million during Q2 2025.
  • For the 3-year period, Inhibrx Biosciences' Research & Development averaged around $44.9 million, with its median value being $37.7 million (2023).
  • Its Research & Development has fluctuated over the past 5 years, first skyrocketed by 80.90% in 2024, then plummeted by 67.08% in 2025.
  • Quarterly analysis of 3 years shows Inhibrx Biosciences' Research & Development stood at $82.1 million in 2023, then tumbled by 59.35% to $33.4 million in 2024, then decreased by 26.63% to $28.5 million in 2025.
  • Its Research & Development stands at $28.5 million for Q3 2025, versus $22.3 million for Q2 2025 and $36.9 million for Q1 2025.